20-F: Cellectis S.A. Files 20-F Report: Outlines Financial Performance and Strategic Objectives

Cellectis S.A. releases its annual report, detailing financial results, strategic plans, and risk factors for the fiscal year ended December 31, 2024.

Summary

• Cellectis S.A., a clinical-stage biopharmaceutical company, has filed its 20-F report for the year ended December 31, 2024.
• The company focuses on developing allogeneic CAR T-cell immunotherapies and gene therapy product candidates.
• Cellectis has incurred net losses since its inception and anticipates continuing to incur significant losses in the foreseeable future; the net loss for 2024 was $36.8 million.
• As of December 31, 2024, Cellectis had cash and cash equivalents of $143.3 million and a fixed-term deposit of $115.8 million, which the company believes will be sufficient to fund operations into 2027.
• The company is advancing clinical trials for UCART22 and UCART20x22 and is collaborating with AstraZeneca on additional product candidates.
• Cellectis relies on licensing agreements with Allogene, Servier, and AstraZeneca, and the success of these relationships is crucial for future revenue.
• AstraZeneca has significant influence over Cellectis, owning approximately 32% of its ordinary shares as of December 31, 2024.
• The company faces substantial competition in the biopharmaceutical industry.
• Cellectis is subject to various risks related to public health crises, that could have material and adverse impacts on its business, financial condition, liquidity, and results of operations.
• The company is subject to complex and evolving regulatory framework, including premarketing regulatory requirements, pricing, reimbursement and cost-containment regulations, and rigorous ongoing regulation of approved products.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While the company has a solid cash position and is advancing clinical trials, it also faces significant financial losses, competition, and regulatory hurdles. The influence of AstraZeneca and potential delays add further uncertainty.

Positives

• Cellectis has cash and cash equivalents of $143.3 million and a fixed-term deposit of $115.8 million, providing a cash runway into 2027.
• The company is advancing clinical trials for UCART22 and UCART20x22.
• Cellectis has licensing agreements with Allogene, Servier, and AstraZeneca, providing potential revenue streams.
• The company operates two in-house manufacturing facilities, enhancing control over production.
• The FDA and the European Commission have granted orphan drug designation to UCART22 and the FDA has granted orphan drug designation to CLLS52 for the treatment of acute lymphoblastic leukemia.

Negatives

• Cellectis has incurred net losses since its inception and anticipates continuing to incur significant losses.
• The company faces substantial competition in the biopharmaceutical industry.
• AstraZeneca has significant influence over Cellectis, which may not always align with the interests of other shareholders.
• The company is subject to complex and evolving regulatory framework, including premarketing regulatory requirements, pricing, reimbursement and cost-containment regulations, and rigorous ongoing regulation of approved products.
• Servier's discontinuation of its involvement in the development of CD19 Products and related disagreements may have adverse consequences.

Risks

• The company may need to raise additional funding, which may not be available on acceptable terms or at all.
• Clinical trials are time-consuming and expensive, with unpredictable outcomes.
• The manufacturing process for product candidates is complex and heavily regulated.
• Negative publicity and increased regulatory scrutiny of gene-editing may damage public perception.
• The company relies on third parties for certain aspects of its operations, which could result in additional costs and delays.
• The company is subject to various risks related to public health crises, that could have material and adverse impacts on its business, financial condition, liquidity, and results of operations.
• The company may be exposed to significant foreign exchange risk, which may adversely affect its financial condition, results of operations and cash flows.
• The company may be classified as a PFIC for 2024 or any future taxable years, which could result in adverse U.S. federal income tax consequences to U.S. holders.

Future Outlook

Cellectis anticipates continuing to incur significant expenses and operating losses for the foreseeable future as it continues its research and development programs and seeks regulatory approvals.

Industry Context

The report acknowledges the intense competition and rapid innovation in the biopharmaceutical and immuno-oncology industries, highlighting the need for Cellectis to compete effectively.

Comparison to Industry Standards

• The document mentions that approved autologous CAR T therapies and those under development have shown frequent rates of CRS, neurotoxicity, serious infections, and prolonged cytopenia, and adverse events have resulted in the death of patients.
• The document mentions that the company is monitoring the safety profile of CLLS52 and carrying out its pharmacovigilance reporting responsibilities as sponsor.
• The document mentions that the company is implementing the use of alementuzumab as a Cellectis investigational medicinal product, coded as CLLS52, in its sponsored clinical protocols in the United States and in the relevant European Union member states.
• The document mentions that the company is conducting clinical studies at specialized centers that are experienced at managing patients with advanced malignancies as well as toxicities associated with immunomodulatory therapies.

Legal Proceedings

• The company has initiated an arbitration proceeding through the Centre de Mdiation et d'Arbitrage de Paris regarding the Servier License Agreement.

Related Party Transactions

• AstraZeneca has significant influence over Cellectis.
• AstraZeneca is a significant collaboration partner for the company.
• The company has entered into a Joint Research and Collaboration Agreement, an Initial Investment Agreement and the SIA with AstraZeneca.

Stakeholder Impact

• Shareholders may experience dilution if the company raises additional capital.
• Employees may be affected by changes in management or restructuring.
• Customers (patients) may benefit from successful development of new therapies.
• Suppliers and creditors may be affected by the company's financial performance.

Next Steps

• Continue advancing clinical trials for UCART22 and UCART20x22.
• Pursue research and development of gene therapy programs.
• Seek regulatory approvals for product candidates.
• Maintain and establish collaborations or obtain additional grant funding.

Key Dates

Keywords

Cellectis, CAR T-cell, immunotherapy, allogeneic, UCART, clinical trials, gene editing, AstraZeneca, Servier, Allogene, financial results, risk factors